CoChat

Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis

Open access
Kalavalapalli, Srilaxmi, Bril, Fernando, Guingab, Joy, Vergara, Ariana, Garrett, Timothy J, Sunny, Nishanth E, Cusi, Kenneth · 2019 · Journal of Endocrinology
Cited by 48

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

Exenatide (Exe) is a glucagon-like peptide (GLP)-1 receptor agonist that enhances insulin secretion and is associated with induction of satiety with weight loss. As mitochondrial dysfunction and lipotoxicity are central features of nonalcoholic steatohepatitis (NASH), we tested whether Exe improved mitochondrial function in this setting. We studied C57BL/6J mice fed for 24 weeks either a control- or high-fructose, high-trans-fat (TFD)-diet (i.e., a NASH model previously validated by our laboratory). For the final 8 weeks, mice were treated with Exe (30 µg/kg/day) or vehicle. Mitochondrial metabolism was assessed by infusion of [13 C 3]propionate, [3,4-13 C 2]glucose and NMR-based 13 C-isotopomer analysis. Exenatide significantly decreased fasting plasma glucose, free fatty acids and triglycerides, as well as adipose tissue insulin resistance. Moreover, Exe reduced 23% hepatic glucose production, 15% tri-carboxylic acid (TCA) cycle flux, 20% anaplerosis and 17% pyruvate cycling resulting in a significant 31% decrease in intrahepatic triglyceride content (P = 0.02). Exenatide improved the lipidomic profile and decreased hepatic lipid byproducts associated with insulin resistance and lipotoxicity, such as diacylglycerols (TFD: 111 ± 13 vs Exe: 64 ± 13 µmol/g protein,P = 0.03) and ceramides (TFD: 1.6 ± 0.1 vs Exe: 1.3 ± 0.1 µmol/g protein,P = 0.03). Exenatide lowered expression of hepatic lipogenic genes (Srebp1C,Cd36) and genes involved in inflammation and fibrosis (Tnfa,Timp1). In conclusion, in a diet-induced mouse model of NASH, Exe ameliorates mitochondrial TCA cycle flux and significantly decreases insulin resistance, steatosis and hepatocyte lipotoxicity. This may have significant clinical implications to the potential mechanism of action of GLP-1 receptor agonists in patients with NASH. Future studies should elucidate the relative contribution of direct vs indirect mechanisms at play.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1530/joe-19-0007

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 48

Metadata

Authors
Kalavalapalli, S., Bril, F., Guingab, J., Vergara, A., Garrett, T. J., Sunny, N. E., & Cusi, K.
Venue
Journal of Endocrinology
Published
2019-06
Volume
241
Issue
3
Pages
293-305
ISSN
  • 0022-0795 (ISSN-L)
  • 1479-6805
OpenAlex
W2946574770
Cited by
48
References
32
FWCI
3.48
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis. https://app.cochat.ai/papers/10.1530/joe-19-0007
The paper
Kalavalapalli, S., Bril, F., Guingab, J., Vergara, A., Garrett, T. J., Sunny, N. E., & Cusi, K. (2019). Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis. Journal of Endocrinology. https://doi.org/10.1530/joe-19-0007

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.